Reducing Animal Testing: Real-time Cell Analysis with Roche's xCELLigence System for the Early Detection of Hepatic Cytotoxicity

(PresseBox) (Penzberg, ) The 3Rs concept of reducing, refining and replacing animal experimentation was developed by W.M.S. Russell and R.L. Burch in their book "The Principles of Humane Experimental Technique" more than 50 years ago. Today, early identification of toxic compounds using cellbased in vitro assays like Roche's (SIX: RO, ROG; OTCQX: RHHBY) xCELLigence System can reduce the number of laboratory animals used for in vivo testing of suboptimal compounds that ultimately fail at later stages of drug testing. A recent study from Roche Pharma and Roche Applied Science (1) describes a comprehensive workflow of in vitro techniques, including realtime cell analysis, biochemical assays, and gene expression analyses for hepatotoxicity assessment.

Hepatotoxic effects of the tested compounds were easily monitored using the xCELLigence System, to generate Cell Index (CI) profiles that quantitate the onset and progress of compoundinduced cell death. Compared to routinely used biochemical endpoint assays, the xCELLigence System showed a higher sensitivity 24 hours posttreatment. Resulting kinetic profiles monitored toxicity from the beginning to end of the experiment; profiles like this are not possible using endpoint assays. Continuous CI recording quantifies cytotoxicity identifying the optimal time point for IC50 calculations. Interestingly, CI profiles revealed dosedependent hepatocyte responses to the tested compounds as early as 6 hours posttreatment.

In the following, the researchers investigated hepatotoxic effects by gene expression analysis at these early time points. Whole genome microarray analysis revealed a significant reproducible change in gene expression 6 hours posttreatment, coinciding with the onset of cell death found in the xCELLigence System data. Subsequent quantitative RT-PCR for a subset of selected genes revealed a significant change in gene expression 6 hours after compound administration, indicating early onset of gene regulation within the first hours posttreatment.

The results of this study emphasize the added value of the described workflow of realtime cell analysis, biochemical endpoint assays, and gene expression analyses. Continuous monitoring using the xCELLigence System easily identified modest cellular effects, providing a versatile way for pinpointing times for downstream proteomic and genomic analyses. Using Roche NimbleGen microarrays for appropriatelytimed molecular analysis assures meaningful and reproducible whole genome expression data for identifying new target genes and possible biomarkers. Gene expression analyses using Universal ProbeLibrary Assays are also now available as pretested Real-Time ready Assays. Combining the xCELLigence System with both wellestablished Roche endpoint assays and this new generation of Roche gene expression assays significantly improves the predictive quality of early safety evaluations that may go on to reduce current levels of animal testing in the future.

(1) M. Schmitz, A. Seiler, M.-A. Watt, R. Alexandridis, H. Walch, F. Boess, A. B. Roth, “Improved Cellular Analysis for the Early Detection of Compound-Induced Hepatic Cytotoxicity to Reduce
Animal Testing”. Roche Applied Science, Cancer Research Application Note No. 5, 2010.


Roche Diagnostics Deutschland GmbH
Sandhofer Str. 116
D-68305 Mannheim
Dr. Burkhard Ziebolz
Roche Applied Science
Head Global Communication
Social Media